Kevin Holman, MBA, RAC leads the REMS and Risk Management Center of Excellence at Janssen Pharmaceuticals, where he built and leads a team that oversees the design, implementation, management, and assessment of risk management programs in the U.S. Throughout his career, Kevin has led and contributed to more than half of the currently-approved shared REMS programs and dozens of REMS programs across various therapeutic areas. Prior to Janssen, he was the Head of US Product Risk Management at Actelion, and has held positions with McKesson Specialty Health, Pfizer, PDR Network and Mallinckrodt in REMS consulting and assessment, regulatory affairs, risk management, and R&D.